---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-044434"
form_type: "8-K"
ticker: "ROIV"
cik: "0001635088"
company_name: "Roivant Sciences Ltd."
filed_at: "2024-10-28T23:59:59+00:00"
generated_at: "2026-05-30T09:41:38.071325+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Roivant subsidiary Dermavant acquired by Organon; merger closed Oct 28, 2024

## Summary
- Organon completed acquisition of Dermavant from Roivant on October 28, 2024, expanding dermatology portfolio.
- VTAMA (tapinarof) cream 1% is FDA-approved for plaque psoriasis; sNDA for atopic dermatitis under review with PDUFA in Q4 2024.
- Dermavant's credit agreement terminated upon closing; all amounts outstanding repaid.
- Roivant President cites win-win outcome; expects to share meaningfully in VTAMA's success via collaboration.

## SEC filing metadata
- accession: 0001140361-24-044434
- form_type: 8-K
- ticker: ROIV
- cik: 0001635088
- company_name: Roivant Sciences Ltd.
- filed_at: 2024-10-28T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1635088/000114036124044434/0001140361-24-044434-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1635088/000114036124044434/ef20037790_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-044434
- JSON: https://secwatch.observer/filing/0001140361-24-044434.json
- Plain text: https://secwatch.observer/filing/0001140361-24-044434.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.